MedDataX Logo

Maternal Pertussis Wholecell Responses

NCT ID: NCT04589312

Last Updated: 2023-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

181 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-21

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pertussis is resurging worldwide. In Africa alone it is estimated that there are 2.1 million cases and 542,000 deaths from pertussis in infants under 1 year with the highest rates of morbidity and mortality in infants \<3 months old, before possible prevention via the infant immunization programme1. To protect these most vulnerable infants, the World Health Organisation (WHO) recommends Tdap vaccination as safe in pregnancy and recommends the use of wP vaccines within the EPI. Maternal antibody following aP vaccination can interfere with infant anti-pertussis antibody responses post infant EPI vaccination, which is of concern in high burden settings such as Uganda. There are therefore multiple factors in this population which may influence the effect of pertussis immunization in pregnancy, and which have not been studied, most notably HIV infection and interference with wP vaccines in infants. The immunogenicity of Tdap in HIV-infected pregnant women has not yet been examined. In addition, to date, the effect of maternal vaccination, placental transfer and infant antibody responses in HEU infants have not been studied at all. There are no studies examining the immune response to wP vaccine administered to infants (EPI recommendation) whose mothers received aP in pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pertussis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

The study will take a 2x2 formation, with four groups:

1. HIV-uninfected women, standard of care vaccines in pregnancy;
2. HIV-uninfected women, Tdap vaccine in pregnancy;
3. HIV-infected women, standard of care vaccines in pregnancy;
4. HIV-infected women, Tdap vaccine in pregnancy.
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Study nursing staff and participants will be blinded to the vaccine given and vaccine syringes will be covered with an opaque label, obscuring the vaccine. Only the preparing pharmacist will be aware of the vaccine used. A study nurse who is blinded to the vaccine given will observe for immediate reactions to the vaccine in a separate room from where the woman will receive her vaccination. This room will have an emergency trolley with appropriate drugs available should these be required.

The laboratory-based research team conducting the assays will be blinded to subject allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women not living with HIV, Td vaccine

Group Type ACTIVE_COMPARATOR

Standard of care vaccines

Intervention Type BIOLOGICAL

Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)

Pregnant women not living with HIV, Tdap vaccine

Group Type EXPERIMENTAL

Boostagen, (BioNet-Asia)

Intervention Type BIOLOGICAL

Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);

Pregnant women living with HIV, Td vaccine

Group Type ACTIVE_COMPARATOR

Standard of care vaccines

Intervention Type BIOLOGICAL

Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)

Pregnant women living with HIV, Tdap vaccine

Group Type EXPERIMENTAL

Boostagen, (BioNet-Asia)

Intervention Type BIOLOGICAL

Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of care vaccines

Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)

Intervention Type BIOLOGICAL

Boostagen, (BioNet-Asia)

Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be a woman aged 18 years or older, inclusive at day of signing the ICF;
* Pregnant woman at \>16 and \<26 weeks gestation, verified by ultrasound scan;
* Documented HIV test during pregnancy taken by rapid test at the screening visit;
* Low risk, singleton pregnancy, as assessed by the study physician based on ultrasound scan and previous obstetric history; and
* The woman is willing to comply with the study procedures, including giving birth at Kawempe National Referral Hospital, remaining in the study area until the infant is 1 year old and is able to provide informed consent for herself and on behalf of the infant

Exclusion Criteria

Any of the following:

* Previous anaphylaxis to any component of Td or Tdap vaccines;
* vaccination is otherwise contraindicated (per product monographs);
* Documented to have received four or more previous tetanus toxoid vaccine doses (as this would prevent randomisation to Tdap group and receipt of two additional tetanus toxoid containing vaccines);
* History of pre-eclampsia or eclampsia in previous pregnancies;
* Gestational diabetes in current pregnancy;
* Rhesus negative mothers;
* Multigravida;
* Previous late stillbirth (defined as loss of pregnancy at any time after 28 weeks gestation);
* Previous low birth weight baby of less than 2.0 kilograms or premature delivery (defined as a delivery before 37 weeks gestation);
* Previous neonatal death (defined as death of an infant within the first 28 days of life);
* Previous delivery of an infant with a known or suspected genetic or chromosomal abnormality;
* History of other significant pregnancy related complications judged likely to affect the safety of the mother or infant or to significantly compromise the endpoint data collected;
* History of other significant neonatal complications judged likely to affect the safety of the mother or infant or to significantly compromise the endpoint data collected;
* Significant maternal chronic illness including but not limited to hypertension requiring treatment, heart disease, lung disease, neurological disorders including a history of epilepsy or recurrent afebrile seizures, kidney disease, liver disease, anaemia and other haematological disorders (including sickle cell), endocrine disorders including known diabetes mellitus, autoimmunity;
* Severe anaemia (less than 7.0g/dL);
* Known Syphilis or hepatitis B (HBV) virus positive or found to be Syphilis or HBV positive during screening;
* Any other condition judged to significantly increase the risks to either the mother or the infant within the current pregnancy (including relevant history from previous pregnancies);
* Receipt of any blood product including human immunoglobulins at any stage during the current pregnancy or plan to receive any blood products during the period or trial participation (receipt of blood products in an emergency or for obstetric reasons will not represent a protocol deviation given such situations are unplanned);
* Clinically suspected or confirmed congenital or acquired clotting or bleeding disorders or the current receipt of medications known to alter clotting or bleeding;
* Any clinically significant signs or symptoms of acute illness, significant abnormalities in vital signs, an axillary temperature of greater than 38.0°C or any recorded fever (greater than 38.0°C) in the preceding 24 hours;
* Two or more symptoms (nausea/vomiting, diarrhoea, headaches, fatigue and myalgia) rated as grade 2 and clinically significant on the maternal systemic reactogenicity scale present at baseline on the day of vaccination;
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily;
* Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure;
* History of being treated for pertussis
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical Research Council

OTHER_GOV

Sponsor Role collaborator

University of British Columbia

OTHER

Sponsor Role collaborator

Public Health England

OTHER_GOV

Sponsor Role collaborator

MU-JHU CARE

OTHER

Sponsor Role collaborator

BioNet-Asia

UNKNOWN

Sponsor Role collaborator

St George's, University of London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kirsty Le Doare, MBBS, PhD

Role: STUDY_CHAIR

St George's, University of London

Manish Sadarangani, MRCPCH, DPHIL, BM.BCh, MA

Role: STUDY_CHAIR

BC Children's Hospital Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MUJHU Care Ltd

Kampala, , Uganda

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Uganda

References

Explore related publications, articles, or registry entries linked to this study.

Nakabembe E, Greenland M, Amaral K, Abu-Raya B, Amone A, Andrews N, Cantrell L, Lesne E, Gorringe A, Halkerston R, Mcstraw N, Dixon L, Hunter OF, Heath PT, Imede E, Kyohere M, Musoke P, Nakimuli A, Sekikubo M, Taylor S, Tusubira V, Sadarangani M, Le Doare K. Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda. Lancet Glob Health. 2025 Jan;13(1):e81-e97. doi: 10.1016/S2214-109X(24)00409-1.

Reference Type DERIVED
PMID: 39706666 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17.0019

Identifier Type: -

Identifier Source: org_study_id